Clinical features and short-term outcomes of cancer patients with suspected and unsuspected pulmonary embolism: the EPIPHANY study

The study aimed to identify predictors of overall 30-day mortality in cancer patients with pulmonary embolism including suspected pulmonary embolism (SPE) and unsuspected pulmonary embolism (UPE) events. Secondary outcomes included 30- and 90-day major bleeding and venous thromboembolism (VTE) recur...

Full description

Saved in:
Bibliographic Details
Published inThe European respiratory journal Vol. 49; no. 1; p. 1600282
Main Authors Font, Carme, Carmona-Bayonas, Alberto, Beato, Carmen, Reig, Òscar, Sáez, Antonia, Jiménez-Fonseca, Paula, Plasencia, Juana M., Calvo-Temprano, David, Sanchez, Marcelo, Benegas, Mariana, Biosca, Mercedes, Varona, Diego, Vicente, Maria Angeles, Faez, Laura, Solís, Maria del Pilar, de la Haba, Irma, Antonio, Maite, Madridano, Olga, Castañon, Eduardo, Martinez, María Jose, Marchena, Pablo, Ramchandani, Avinash, Dominguez, Angel, Puerta, Alejandro, Martinez de la Haza, David, Pueyo, Jesus, Hernandez, Susana, Fernandez-Plaza, Angela, Martinez-Encarnacion, Lourdes, Martin, Mar, Marin, Gema, Ayala, Francisco, Vicente, Vicente, Otero, Remedios
Format Journal Article
LanguageEnglish
Published England European Respiratory Society Journals Ltd 01.01.2017
Subjects
Online AccessGet full text
ISSN0903-1936
1399-3003
DOI10.1183/13993003.00282-2016

Cover

Abstract The study aimed to identify predictors of overall 30-day mortality in cancer patients with pulmonary embolism including suspected pulmonary embolism (SPE) and unsuspected pulmonary embolism (UPE) events. Secondary outcomes included 30- and 90-day major bleeding and venous thromboembolism (VTE) recurrence. The study cohort included 1033 consecutive patients with pulmonary embolism from the multicentre observational ambispective EPIPHANY study (March 2006–October 2014). A subgroup of 497 patients prospectively assessed for the study were subclassified into three work-up scenarios (SPE, truly asymptomatic UPE and UPE with symptoms) to assess outcomes. The overall 30-day mortality rate was 14%. The following variables were associated with the overall 30-day mortality on multivariate analysis: VTE history, upper gastrointestinal cancers, metastatic disease, cancer progression, performance status, arterial hypotension <100 mmHg, heart rate >110 beats·min −1 , basal oxygen saturation <90% and SPE ( versus overall UPE). The overall 30-day mortality was significantly lower in patients with truly asymptomatic UPE events (3%) compared with those with UPE-S (20%) and SPE (21%) (p<0.0001). Thirty- and 90-day VTE recurrence and major bleeding rates were similar in all the groups. In conclusion, variables associated with the severity of cancer and pulmonary embolism were associated with short-term mortality. Our findings may help to develop pulmonary embolism risk-assessment models in this setting.
AbstractList The study aimed to identify predictors of overall 30-day mortality in cancer patients with pulmonary embolism including suspected pulmonary embolism (SPE) and unsuspected pulmonary embolism (UPE) events. Secondary outcomes included 30- and 90-day major bleeding and venous thromboembolism (VTE) recurrence.The study cohort included 1033 consecutive patients with pulmonary embolism from the multicentre observational ambispective EPIPHANY study (March 2006-October 2014). A subgroup of 497 patients prospectively assessed for the study were subclassified into three work-up scenarios (SPE, truly asymptomatic UPE and UPE with symptoms) to assess outcomes.The overall 30-day mortality rate was 14%. The following variables were associated with the overall 30-day mortality on multivariate analysis: VTE history, upper gastrointestinal cancers, metastatic disease, cancer progression, performance status, arterial hypotension <100 mmHg, heart rate >110 beats·min-1, basal oxygen saturation <90% and SPE (versus overall UPE).The overall 30-day mortality was significantly lower in patients with truly asymptomatic UPE events (3%) compared with those with UPE-S (20%) and SPE (21%) (p<0.0001). Thirty- and 90-day VTE recurrence and major bleeding rates were similar in all the groups.In conclusion, variables associated with the severity of cancer and pulmonary embolism were associated with short-term mortality. Our findings may help to develop pulmonary embolism risk-assessment models in this setting.
The study aimed to identify predictors of overall 30-day mortality in cancer patients with pulmonary embolism including suspected pulmonary embolism (SPE) and unsuspected pulmonary embolism (UPE) events. Secondary outcomes included 30- and 90-day major bleeding and venous thromboembolism (VTE) recurrence. The study cohort included 1033 consecutive patients with pulmonary embolism from the multicentre observational ambispective EPIPHANY study (March 2006–October 2014). A subgroup of 497 patients prospectively assessed for the study were subclassified into three work-up scenarios (SPE, truly asymptomatic UPE and UPE with symptoms) to assess outcomes. The overall 30-day mortality rate was 14%. The following variables were associated with the overall 30-day mortality on multivariate analysis: VTE history, upper gastrointestinal cancers, metastatic disease, cancer progression, performance status, arterial hypotension <100 mmHg, heart rate >110 beats·min −1 , basal oxygen saturation <90% and SPE ( versus overall UPE). The overall 30-day mortality was significantly lower in patients with truly asymptomatic UPE events (3%) compared with those with UPE-S (20%) and SPE (21%) (p<0.0001). Thirty- and 90-day VTE recurrence and major bleeding rates were similar in all the groups. In conclusion, variables associated with the severity of cancer and pulmonary embolism were associated with short-term mortality. Our findings may help to develop pulmonary embolism risk-assessment models in this setting.
The study aimed to identify predictors of overall 30-day mortality in cancer patients with pulmonary embolism including suspected pulmonary embolism (SPE) and unsuspected pulmonary embolism (UPE) events. Secondary outcomes included 30- and 90-day major bleeding and venous thromboembolism (VTE) recurrence.The study cohort included 1033 consecutive patients with pulmonary embolism from the multicentre observational ambispective EPIPHANY study (March 2006-October 2014). A subgroup of 497 patients prospectively assessed for the study were subclassified into three work-up scenarios (SPE, truly asymptomatic UPE and UPE with symptoms) to assess outcomes.The overall 30-day mortality rate was 14%. The following variables were associated with the overall 30-day mortality on multivariate analysis: VTE history, upper gastrointestinal cancers, metastatic disease, cancer progression, performance status, arterial hypotension <100 mmHg, heart rate >110 beats·min , basal oxygen saturation <90% and SPE (versus overall UPE).The overall 30-day mortality was significantly lower in patients with truly asymptomatic UPE events (3%) compared with those with UPE-S (20%) and SPE (21%) (p<0.0001). Thirty- and 90-day VTE recurrence and major bleeding rates were similar in all the groups.In conclusion, variables associated with the severity of cancer and pulmonary embolism were associated with short-term mortality. Our findings may help to develop pulmonary embolism risk-assessment models in this setting.
The study aimed to identify predictors of overall 30-day mortality in cancer patients with pulmonary embolism including suspected pulmonary embolism (SPE) and unsuspected pulmonary embolism (UPE) events. Secondary outcomes included 30- and 90-day major bleeding and venous thromboembolism (VTE) recurrence.The study cohort included 1033 consecutive patients with pulmonary embolism from the multicentre observational ambispective EPIPHANY study (March 2006-October 2014). A subgroup of 497 patients prospectively assessed for the study were subclassified into three work-up scenarios (SPE, truly asymptomatic UPE and UPE with symptoms) to assess outcomes.The overall 30-day mortality rate was 14%. The following variables were associated with the overall 30-day mortality on multivariate analysis: VTE history, upper gastrointestinal cancers, metastatic disease, cancer progression, performance status, arterial hypotension <100mmHg, heart rate >110beats.min-1, basal oxygen saturation <90% and SPE (versus overall UPE).The overall 30-day mortality was significantly lower in patients with truly asymptomatic UPE events (3%) compared with those with UPE-S (20%) and SPE (21%) (p<0.0001). Thirty- and 90-day VTE recurrence and major bleeding rates were similar in all the groups.In conclusion, variables associated with the severity of cancer and pulmonary embolism were associated with short-term mortality. Our findings may help to develop pulmonary embolism risk-assessment models in this setting.
The study aimed to identify predictors of overall 30-day mortality in cancer patients with pulmonary embolism including suspected pulmonary embolism (SPE) and unsuspected pulmonary embolism (UPE) events. Secondary outcomes included 30- and 90-day major bleeding and venous thromboembolism (VTE) recurrence.The study cohort included 1033 consecutive patients with pulmonary embolism from the multicentre observational ambispective EPIPHANY study (March 2006–October 2014). A subgroup of 497 patients prospectively assessed for the study were subclassified into three work-up scenarios (SPE, truly asymptomatic UPE and UPE with symptoms) to assess outcomes.The overall 30-day mortality rate was 14%. The following variables were associated with the overall 30-day mortality on multivariate analysis: VTE history, upper gastrointestinal cancers, metastatic disease, cancer progression, performance status, arterial hypotension <100 mmHg, heart rate >110 beats·min−1, basal oxygen saturation <90% and SPE (versus overall UPE).The overall 30-day mortality was significantly lower in patients with truly asymptomatic UPE events (3%) compared with those with UPE-S (20%) and SPE (21%) (p<0.0001). Thirty- and 90-day VTE recurrence and major bleeding rates were similar in all the groups.In conclusion, variables associated with the severity of cancer and pulmonary embolism were associated with short-term mortality. Our findings may help to develop pulmonary embolism risk-assessment models in this setting.
Author Jiménez-Fonseca, Paula
Pueyo, Jesus
Calvo-Temprano, David
Carmona-Bayonas, Alberto
Sáez, Antonia
Antonio, Maite
Otero, Remedios
Fernandez-Plaza, Angela
Font, Carme
Martinez-Encarnacion, Lourdes
Reig, Òscar
Benegas, Mariana
Solís, Maria del Pilar
Faez, Laura
Varona, Diego
Madridano, Olga
Vicente, Maria Angeles
Ayala, Francisco
de la Haba, Irma
Plasencia, Juana M.
Castañon, Eduardo
Marin, Gema
Biosca, Mercedes
Puerta, Alejandro
Martin, Mar
Hernandez, Susana
Marchena, Pablo
Vicente, Vicente
Beato, Carmen
Sanchez, Marcelo
Martinez de la Haza, David
Ramchandani, Avinash
Martinez, María Jose
Dominguez, Angel
Author_xml – sequence: 1
  givenname: Carme
  surname: Font
  fullname: Font, Carme
– sequence: 2
  givenname: Alberto
  surname: Carmona-Bayonas
  fullname: Carmona-Bayonas, Alberto
– sequence: 3
  givenname: Carmen
  surname: Beato
  fullname: Beato, Carmen
– sequence: 4
  givenname: Òscar
  surname: Reig
  fullname: Reig, Òscar
– sequence: 5
  givenname: Antonia
  surname: Sáez
  fullname: Sáez, Antonia
– sequence: 6
  givenname: Paula
  surname: Jiménez-Fonseca
  fullname: Jiménez-Fonseca, Paula
– sequence: 7
  givenname: Juana M.
  surname: Plasencia
  fullname: Plasencia, Juana M.
– sequence: 8
  givenname: David
  surname: Calvo-Temprano
  fullname: Calvo-Temprano, David
– sequence: 9
  givenname: Marcelo
  surname: Sanchez
  fullname: Sanchez, Marcelo
– sequence: 10
  givenname: Mariana
  surname: Benegas
  fullname: Benegas, Mariana
– sequence: 11
  givenname: Mercedes
  surname: Biosca
  fullname: Biosca, Mercedes
– sequence: 12
  givenname: Diego
  surname: Varona
  fullname: Varona, Diego
– sequence: 13
  givenname: Maria Angeles
  surname: Vicente
  fullname: Vicente, Maria Angeles
– sequence: 14
  givenname: Laura
  surname: Faez
  fullname: Faez, Laura
– sequence: 15
  givenname: Maria del Pilar
  surname: Solís
  fullname: Solís, Maria del Pilar
– sequence: 16
  givenname: Irma
  surname: de la Haba
  fullname: de la Haba, Irma
– sequence: 17
  givenname: Maite
  surname: Antonio
  fullname: Antonio, Maite
– sequence: 18
  givenname: Olga
  surname: Madridano
  fullname: Madridano, Olga
– sequence: 19
  givenname: Eduardo
  surname: Castañon
  fullname: Castañon, Eduardo
– sequence: 20
  givenname: María Jose
  surname: Martinez
  fullname: Martinez, María Jose
– sequence: 21
  givenname: Pablo
  surname: Marchena
  fullname: Marchena, Pablo
– sequence: 22
  givenname: Avinash
  surname: Ramchandani
  fullname: Ramchandani, Avinash
– sequence: 23
  givenname: Angel
  surname: Dominguez
  fullname: Dominguez, Angel
– sequence: 24
  givenname: Alejandro
  surname: Puerta
  fullname: Puerta, Alejandro
– sequence: 25
  givenname: David
  surname: Martinez de la Haza
  fullname: Martinez de la Haza, David
– sequence: 26
  givenname: Jesus
  surname: Pueyo
  fullname: Pueyo, Jesus
– sequence: 27
  givenname: Susana
  surname: Hernandez
  fullname: Hernandez, Susana
– sequence: 28
  givenname: Angela
  surname: Fernandez-Plaza
  fullname: Fernandez-Plaza, Angela
– sequence: 29
  givenname: Lourdes
  surname: Martinez-Encarnacion
  fullname: Martinez-Encarnacion, Lourdes
– sequence: 30
  givenname: Mar
  surname: Martin
  fullname: Martin, Mar
– sequence: 31
  givenname: Gema
  surname: Marin
  fullname: Marin, Gema
– sequence: 32
  givenname: Francisco
  surname: Ayala
  fullname: Ayala, Francisco
– sequence: 33
  givenname: Vicente
  surname: Vicente
  fullname: Vicente, Vicente
– sequence: 34
  givenname: Remedios
  surname: Otero
  fullname: Otero, Remedios
BackLink https://www.ncbi.nlm.nih.gov/pubmed/28052954$$D View this record in MEDLINE/PubMed
BookMark eNqNkU1rFTEUhoNU7G31FwgScONmak7OfCTuyqXaQtEudOFqyGTOcKfMJGM-kG795c69bRW6EFfhvDzvgZznhB0574ix1yDOABS-B9QahcAzIaSShRRQP2ObfVrs4yO2EVpgARrrY3YS461YiRLhBTuWSlRSV-WG_dpOoxutmfhAJuVAkRvX87jzIRWJwsx9TtbPa-4Hbo2zFPhi0kguRf5zTDsec1zIJuoPzez-zkueZu9MuOM0d34a4_yBpx3xi5urm8vzz995TLm_e8meD2aK9OrhPWXfPl583V4W118-XW3PrwtbAqSiN7obZEmiMVCj0kY1RoimBFQS-k6j1UIiYaW6DqVWVGMFRjZlr9XQA-Ape3e_dwn-R6aY2nmMlqbJOPI5tqBqhShk2fwHWlWNBoliRd8-QW99Dm79SAtaoV7PfKDePFC5m6lvlzDO613aRxErgPeADT7GQMMfBES7190-6m4Putu97rWln7TsmFY53qVgxumf3d9QC60b
CitedBy_id crossref_primary_10_3892_ol_2022_13288
crossref_primary_10_1016_j_ijcard_2022_04_068
crossref_primary_10_1016_j_ijcard_2022_09_049
crossref_primary_10_1016_j_jaccao_2022_07_008
crossref_primary_10_1016_j_pupt_2019_04_001
crossref_primary_10_3310_HRCW7937
crossref_primary_10_23736_S0392_9590_19_04110_5
crossref_primary_10_1055_a_1897_7061
crossref_primary_10_1007_s12094_017_1632_3
crossref_primary_10_1111_jth_14423
crossref_primary_10_3390_jcm11195650
crossref_primary_10_1111_jth_15435
crossref_primary_10_1055_s_0042_1755605
crossref_primary_10_3390_ijerph18020394
crossref_primary_10_1177_10760296231155177
crossref_primary_10_1371_journal_pone_0222149
crossref_primary_10_1182_blood_2018_08_835595
crossref_primary_10_1183_13993003_02723_2020
crossref_primary_10_1186_s44201_022_00004_7
crossref_primary_10_1093_oncolo_oyae334
crossref_primary_10_3390_cancers14184510
crossref_primary_10_1007_s00520_022_07131_1
crossref_primary_10_1186_s12885_017_3719_1
crossref_primary_10_3390_jcm11236954
crossref_primary_10_1111_jth_15489
crossref_primary_10_1177_10760296231212482
crossref_primary_10_1186_s12959_023_00502_6
crossref_primary_10_17826_cumj_1460163
crossref_primary_10_1016_j_amjmed_2021_01_031
crossref_primary_10_1182_asheducation_2017_1_128
crossref_primary_10_1016_j_jaccao_2022_10_001
crossref_primary_10_1200_JCO_18_01977
crossref_primary_10_1007_s00520_018_4380_1
crossref_primary_10_1007_s12094_017_1692_4
crossref_primary_10_1016_j_rmr_2023_03_006
crossref_primary_10_1055_s_0040_1716738
crossref_primary_10_1183_13993003_00028_2020
crossref_primary_10_1182_blood_2017_05_787929
crossref_primary_10_2147_CMAR_S329329
crossref_primary_10_3389_fcvm_2023_1118385
crossref_primary_10_1111_ejh_13877
crossref_primary_10_1183_13993003_02225_2016
crossref_primary_10_1007_s12094_017_1713_3
crossref_primary_10_1007_s00520_018_4235_9
crossref_primary_10_1007_s11239_024_02960_9
crossref_primary_10_1016_j_rmed_2024_107920
crossref_primary_10_1038_bjc_2017_48
crossref_primary_10_1177_2333794X211009094
crossref_primary_10_1016_j_ijcard_2023_131271
crossref_primary_10_1016_j_amjcard_2018_11_009
Cites_doi 10.1200/JCO.2014.56.5184
10.1056/NEJM200012213432504
10.1016/j.lungcan.2012.08.007
10.1056/NEJMra072753
10.1016/j.thromres.2010.03.016
10.1111/j.1538-7836.2005.01204.x
10.1001/jama.1990.03440200057023
10.1001/archinternmed.2010.199
10.1016/j.thromres.2012.03.015
10.1016/B978-1-4377-1604-7.00006-3
10.1016/S0049-3848(14)50021-7
10.1055/s-0037-1615716
10.1111/j.1538-7836.2010.04114.x
10.1200/JCO.2009.23.5788
10.1186/1472-6963-13-235
10.1160/TH08-05-0285
10.1111/jth.12883
10.1016/S0025-7753(15)30016-6
10.6004/jnccn.2014.0038
10.1016/j.thromres.2016.05.010
10.1016/j.lungcan.2009.11.015
10.1093/eurheartj/ehu283
10.1056/NEJMra0907731
10.1200/JCO.2011.37.2730
10.1111/jth.13172
10.1016/S0049-3848(14)50028-X
10.1200/JCO.2010.34.0984
10.1200/JCO.2006.06.5870
10.1161/CIRCULATIONAHA.107.726232
10.1056/NEJM199205073261902
10.1097/00000421-198212000-00014
10.1016/j.chest.2015.11.026
10.1378/chest.12-0964
10.1111/jth.12325
10.1055/s-0037-1614065
10.1093/annonc/mdq720
10.1378/chest.15-0808
10.1016/S0049-3848(15)50432-5
10.1093/jnci/92.3.205
ContentType Journal Article
Copyright Copyright ©ERS 2017.
Copyright European Respiratory Society Journals Ltd. Jan 2017
Copyright_xml – notice: Copyright ©ERS 2017.
– notice: Copyright European Respiratory Society Journals Ltd. Jan 2017
CorporateAuthor Asociación para la Investigación de la Enfermedad Tromboembólica de la región de Murcia
CorporateAuthor_xml – name: Asociación para la Investigación de la Enfermedad Tromboembólica de la región de Murcia
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7T5
H94
7X8
DOI 10.1183/13993003.00282-2016
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Immunology Abstracts
AIDS and Cancer Research Abstracts
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
AIDS and Cancer Research Abstracts
Immunology Abstracts
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
CrossRef
MEDLINE
AIDS and Cancer Research Abstracts
AIDS and Cancer Research Abstracts
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1399-3003
EndPage 1600282
ExternalDocumentID 28052954
10_1183_13993003_00282_2016
Genre Multicenter Study
Journal Article
Observational Study
GroupedDBID ---
.55
.GJ
18M
1OC
2WC
31~
3O-
53G
5GY
5RE
5VS
8-1
AADJU
AAFWJ
AAYXX
AAZMJ
ABCQX
ABJNI
ABOCM
ABSQV
ACEMG
ACGFO
ACPRK
ACXQS
ADBBV
ADDZX
ADMOG
ADYFA
AENEX
AFFNX
AFHIN
AFZJQ
AIZTS
AJAOE
ALMA_UNASSIGNED_HOLDINGS
BAWUL
BTFSW
CAG
CITATION
COF
CS3
DIK
E3Z
EBS
EJD
F5P
F9R
GX1
H13
INIJC
J5H
KQ8
L7B
LH4
LW6
OK1
P2P
PQQKQ
R0Z
RHI
TER
TR2
W8F
WOQ
X7M
ZE2
ZGI
ZXP
~02
CGR
CUY
CVF
ECM
EIF
NPM
RHF
7T5
H94
7X8
ID FETCH-LOGICAL-c411t-da9bf24e07a16389a87a007413821db93c9023e358bb3298e6351a274d98fd113
ISSN 0903-1936
IngestDate Thu Sep 04 23:25:41 EDT 2025
Fri Sep 05 11:21:37 EDT 2025
Sun Jun 29 16:42:17 EDT 2025
Wed Feb 19 02:43:22 EST 2025
Tue Jul 01 05:33:22 EDT 2025
Thu Apr 24 23:01:23 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
License Copyright ©ERS 2017.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c411t-da9bf24e07a16389a87a007413821db93c9023e358bb3298e6351a274d98fd113
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ObjectType-Undefined-3
OpenAccessLink https://erj.ersjournals.com/content/erj/49/1/1600282.full.pdf
PMID 28052954
PQID 1983929530
PQPubID 105654
PageCount 1
ParticipantIDs proquest_miscellaneous_1868330247
proquest_miscellaneous_1855791230
proquest_journals_1983929530
pubmed_primary_28052954
crossref_primary_10_1183_13993003_00282_2016
crossref_citationtrail_10_1183_13993003_00282_2016
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2017-01-01
PublicationDateYYYYMMDD 2017-01-01
PublicationDate_xml – month: 01
  year: 2017
  text: 2017-01-01
  day: 01
PublicationDecade 2010
PublicationPlace England
PublicationPlace_xml – name: England
– name: Copenhagen
PublicationTitle The European respiratory journal
PublicationTitleAlternate Eur Respir J
PublicationYear 2017
Publisher European Respiratory Society Journals Ltd
Publisher_xml – name: European Respiratory Society Journals Ltd
References 2024102100182601000_49.1.1600282.18
2024102100182601000_49.1.1600282.39
2024102100182601000_49.1.1600282.16
2024102100182601000_49.1.1600282.38
Wicki (2024102100182601000_49.1.1600282.4) 2000; 84
Becattini (2024102100182601000_49.1.1600282.29) 2016; 149
2024102100182601000_49.1.1600282.19
Monreal (2024102100182601000_49.1.1600282.33) 2001; 85
2024102100182601000_49.1.1600282.10
2024102100182601000_49.1.1600282.32
2024102100182601000_49.1.1600282.31
Kuderer (2024102100182601000_49.1.1600282.26) 2014; 133 Suppl
2024102100182601000_49.1.1600282.36
2024102100182601000_49.1.1600282.13
2024102100182601000_49.1.1600282.35
2024102100182601000_49.1.1600282.34
2024102100182601000_49.1.1600282.11
2024102100182601000_49.1.1600282.2
2024102100182601000_49.1.1600282.3
Falanga (2024102100182601000_49.1.1600282.30) 2015; 135: Suppl 1
2024102100182601000_49.1.1600282.1
den Exter (2024102100182601000_49.1.1600282.15) 2013; 11
Palmer (2024102100182601000_49.1.1600282.37) 2013; 13
2024102100182601000_49.1.1600282.28
2024102100182601000_49.1.1600282.8
2024102100182601000_49.1.1600282.27
2024102100182601000_49.1.1600282.6
2024102100182601000_49.1.1600282.7
2024102100182601000_49.1.1600282.20
2024102100182601000_49.1.1600282.25
2024102100182601000_49.1.1600282.24
Font (2024102100182601000_49.1.1600282.21) 2015; 144 Suppl 1
2024102100182601000_49.1.1600282.23
Carmona-Bayonas (2024102100182601000_49.1.1600282.9) 2016; 143
2024102100182601000_49.1.1600282.22
Font (2024102100182601000_49.1.1600282.12) 2011; 23
Donzé (2024102100182601000_49.1.1600282.5) 2008; 100
van Es (2024102100182601000_49.1.1600282.14) 2014; 133
den Exter (2024102100182601000_49.1.1600282.17) 2012; 29
References_xml – ident: 2024102100182601000_49.1.1600282.39
  doi: 10.1200/JCO.2014.56.5184
– ident: 2024102100182601000_49.1.1600282.1
  doi: 10.1056/NEJM200012213432504
– ident: 2024102100182601000_49.1.1600282.13
  doi: 10.1016/j.lungcan.2012.08.007
– ident: 2024102100182601000_49.1.1600282.31
  doi: 10.1056/NEJMra072753
– ident: 2024102100182601000_49.1.1600282.10
  doi: 10.1016/j.thromres.2010.03.016
– ident: 2024102100182601000_49.1.1600282.24
  doi: 10.1111/j.1538-7836.2005.01204.x
– ident: 2024102100182601000_49.1.1600282.22
  doi: 10.1001/jama.1990.03440200057023
– ident: 2024102100182601000_49.1.1600282.6
  doi: 10.1001/archinternmed.2010.199
– ident: 2024102100182601000_49.1.1600282.7
  doi: 10.1016/j.thromres.2012.03.015
– ident: 2024102100182601000_49.1.1600282.23
  doi: 10.1016/B978-1-4377-1604-7.00006-3
– volume: 133 Suppl
  start-page: S122
  year: 2014
  ident: 2024102100182601000_49.1.1600282.26
  article-title: Guidelines for treatment and prevention of venous thromboembolism among patients with cancer
  publication-title: Thromb Res
  doi: 10.1016/S0049-3848(14)50021-7
– volume: 85
  start-page: 771
  year: 2001
  ident: 2024102100182601000_49.1.1600282.33
  article-title: Prospective study on the usefulness of lung scan in patients with deep vein thrombosis of the lower limbs
  publication-title: Thromb Haemost
  doi: 10.1055/s-0037-1615716
– ident: 2024102100182601000_49.1.1600282.16
  doi: 10.1111/j.1538-7836.2010.04114.x
– ident: 2024102100182601000_49.1.1600282.36
  doi: 10.1200/JCO.2009.23.5788
– volume: 13
  start-page: 235
  year: 2013
  ident: 2024102100182601000_49.1.1600282.37
  article-title: Developing a complex intervention for outpatient management of incidentally diagnosed pulmonary embolism in cancerpatients
  publication-title: BMC Health Serv Res
  doi: 10.1186/1472-6963-13-235
– volume: 100
  start-page: 943
  year: 2008
  ident: 2024102100182601000_49.1.1600282.5
  article-title: Prospective validation of the pulmonary embolism severity index: a clinical prognostic model for pulmonary embolism
  publication-title: Thromb Haemost
  doi: 10.1160/TH08-05-0285
– ident: 2024102100182601000_49.1.1600282.20
  doi: 10.1111/jth.12883
– volume: 144 Suppl 1
  start-page: 31
  year: 2015
  ident: 2024102100182601000_49.1.1600282.21
  article-title: Pulmonary embolism in patients with cancer: foundations of the EPIPHANY study
  publication-title: Med Clin (Barc)
  doi: 10.1016/S0025-7753(15)30016-6
– ident: 2024102100182601000_49.1.1600282.25
  doi: 10.6004/jnccn.2014.0038
– volume: 143
  start-page: 76
  year: 2016
  ident: 2024102100182601000_49.1.1600282.9
  article-title: On the necessity of new decision-making methods for cancer-associated, symptomatic, pulmonary embolism
  publication-title: Thromb Res
  doi: 10.1016/j.thromres.2016.05.010
– ident: 2024102100182601000_49.1.1600282.11
  doi: 10.1016/j.lungcan.2009.11.015
– ident: 2024102100182601000_49.1.1600282.19
  doi: 10.1093/eurheartj/ehu283
– ident: 2024102100182601000_49.1.1600282.32
  doi: 10.1056/NEJMra0907731
– ident: 2024102100182601000_49.1.1600282.35
  doi: 10.1200/JCO.2011.37.2730
– ident: 2024102100182601000_49.1.1600282.38
  doi: 10.1111/jth.13172
– volume: 133
  start-page: S172
  year: 2014
  ident: 2024102100182601000_49.1.1600282.14
  article-title: Cancer-associated unsuspected pulmonary embolism
  publication-title: Thromb Res
  doi: 10.1016/S0049-3848(14)50028-X
– volume: 29
  start-page: 2405
  year: 2012
  ident: 2024102100182601000_49.1.1600282.17
  article-title: Risk of recurrent venous thromboembolism and mortality in patients with cancer incidentally diagnosed with pulmonary embolism: a comparison with symptomatic patients
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2010.34.0984
– ident: 2024102100182601000_49.1.1600282.34
  doi: 10.1200/JCO.2006.06.5870
– ident: 2024102100182601000_49.1.1600282.3
  doi: 10.1161/CIRCULATIONAHA.107.726232
– ident: 2024102100182601000_49.1.1600282.2
  doi: 10.1056/NEJM199205073261902
– ident: 2024102100182601000_49.1.1600282.27
  doi: 10.1097/00000421-198212000-00014
– ident: 2024102100182601000_49.1.1600282.18
  doi: 10.1016/j.chest.2015.11.026
– ident: 2024102100182601000_49.1.1600282.8
  doi: 10.1378/chest.12-0964
– volume: 11
  start-page: 1620
  year: 2013
  ident: 2024102100182601000_49.1.1600282.15
  article-title: Embolic burden of incidental pulmonary embolism diagnosed on routinely performed contrast-enhanced computed tomography imaging in cancer patients
  publication-title: J Thromb Haemost
  doi: 10.1111/jth.12325
– volume: 84
  start-page: 548
  year: 2000
  ident: 2024102100182601000_49.1.1600282.4
  article-title: Predicting adverse outcome in patients with acute pulmonary embolism: A risk score
  publication-title: Thromb Haemost
  doi: 10.1055/s-0037-1614065
– volume: 23
  start-page: 2101
  year: 2011
  ident: 2024102100182601000_49.1.1600282.12
  article-title: Incidental versus symptomatic venous thrombosis incancer patients. Analysis of a prospective observational series with 340 consecutive patients
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdq720
– volume: 149
  start-page: 192
  year: 2016
  ident: 2024102100182601000_49.1.1600282.29
  article-title: Risk stratification of patients with acute symptomatic pulmonary embolism based on presence or absence of lower extremity deep vein thrombosis: systematic review and meta-analysis
  publication-title: Chest
  doi: 10.1378/chest.15-0808
– volume: 135: Suppl 1
  start-page: S8
  year: 2015
  ident: 2024102100182601000_49.1.1600282.30
  article-title: The mechanisms of cancer-associated thrombosis
  publication-title: Thromb Res
  doi: 10.1016/S0049-3848(15)50432-5
– ident: 2024102100182601000_49.1.1600282.28
  doi: 10.1093/jnci/92.3.205
SSID ssj0016431
Score 2.4456923
Snippet The study aimed to identify predictors of overall 30-day mortality in cancer patients with pulmonary embolism including suspected pulmonary embolism (SPE) and...
SourceID proquest
pubmed
crossref
SourceType Aggregation Database
Index Database
Enrichment Source
StartPage 1600282
SubjectTerms Adolescent
Adult
Aged
Aged, 80 and over
Bleeding
Cancer
Cohort Studies
Embolism
Embolisms
Female
Health risk assessment
Heart rate
Hemorrhage - epidemiology
Humans
Hypotension
Logistic Models
Lung cancer
Male
Metastases
Middle Aged
Mortality
Multivariate Analysis
Neoplasms - complications
Neoplasms - mortality
Pulmonary arteries
Pulmonary Embolism - diagnostic imaging
Pulmonary Embolism - epidemiology
Pulmonary embolisms
Risk Assessment
Risk Factors
Spain - epidemiology
Thromboembolism
Time Factors
Tomography, X-Ray Computed
Venous Thromboembolism - diagnostic imaging
Venous Thromboembolism - epidemiology
Young Adult
Title Clinical features and short-term outcomes of cancer patients with suspected and unsuspected pulmonary embolism: the EPIPHANY study
URI https://www.ncbi.nlm.nih.gov/pubmed/28052954
https://www.proquest.com/docview/1983929530
https://www.proquest.com/docview/1855791230
https://www.proquest.com/docview/1868330247
Volume 49
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAFT
  databaseName: Open Access Digital Library
  customDbUrl:
  eissn: 1399-3003
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0016431
  issn: 0903-1936
  databaseCode: KQ8
  dateStart: 19880101
  isFulltext: true
  titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html
  providerName: Colorado Alliance of Research Libraries
– providerCode: PRVBFR
  databaseName: Free Medical Journals
  customDbUrl:
  eissn: 1399-3003
  dateEnd: 20240330
  omitProxy: true
  ssIdentifier: ssj0016431
  issn: 0903-1936
  databaseCode: DIK
  dateStart: 19940101
  isFulltext: true
  titleUrlDefault: http://www.freemedicaljournals.com
  providerName: Flying Publisher
– providerCode: PRVFQY
  databaseName: GFMER Free Medical Journals
  customDbUrl:
  eissn: 1399-3003
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0016431
  issn: 0903-1936
  databaseCode: GX1
  dateStart: 0
  isFulltext: true
  titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php
  providerName: Geneva Foundation for Medical Education and Research
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1db9MwFLXKkBAviG8KAxmJ8VLC4jgfDm-j6lRg6wZqpfIUOYkDm7qktMkDPPJv-Rdc23GSQamAl7RJk9rJPbGP7XvPRegZ8z0Sx3YAFsiE5YZJaHHuJpbr2KmbpAJ6MBngfDzxxzP37dyb93o_Ol5LVRm_TL5tjCv5H6vCMbCrjJL9B8s2fwoH4DvYF7ZgYdj-lY2HJqwxE0qfU-strz8DpbZkkzsoqhLK1bqyibTvygipro1zugq1FEqwdVDl7f6yWsB9qFjdi7hY1A4akqaOTt-cjg8mHzvStOct5prp_VVnEb97N6rLy0vpanLRoEruQGnWa_4VPnSGZKm-VRbNfIGcHtAXtcFr4uzT4GRvONxj9jrhq-4UBgl-mcJoKvahUzHjtFrz8nXHy0nNXkqXupDWKtq67QauZVHbpt3GXeuhXgKxbqmJr4abnY6_c-T3foVJfQtZgixAe98CFMkGFe_JSXQ4OzqKpqP59PnyiyUTnElHgDrbyxV01Ql8XybbePe-XfACYqiSO5r7qgWyoNz9DaVeJlF_GBkphjS9iW7UjxAfaJzeQj2R30bXjmvnjTvou4ErNnDFADrcwhUbuOIiwxqu2MAVS7jiBp7qyg5ccQNXbOD6CgNYsQErVmC9i2aHo-lwbNUpQKzEJaS0Uh7GmeMKO-By4BByFnDFgilzSBqHNAmBdArqsTimTsgE8GfCncBNQ5alhNB7aCcvcvEAYc-hnoi5k7kpARIW8DSwEyCwAQfWSz2_jxzzTKOk1seXaVoWkRonMxoZQ0TKEJE0RB-9aC5aanmY7afvGmNF9Zu3jkioBiketfvoafMztPJy6Y7noqjgHOZ5QQgsc-s5PqMUOHfQR_c1EJo6OUyv6D_cXoFH6Hr7fu6inXJVicdAusv4iYLrTxON2JQ
linkProvider Colorado Alliance of Research Libraries
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Clinical+features+and+short-term+outcomes+of+cancer+patients+with+suspected+and+unsuspected+pulmonary+embolism%3A+the+EPIPHANY+study&rft.jtitle=The+European+respiratory+journal&rft.au=Font+Carme&rft.au=Carmona-Bayonas%2C+Alberto&rft.au=Beato+Carmen&rft.au=Reig+O%CC%80scar&rft.date=2017-01-01&rft.pub=European+Respiratory+Society+Journals+Ltd&rft.issn=0903-1936&rft.eissn=1399-3003&rft.volume=49&rft.issue=1&rft.spage=1600282&rft.epage=1600282&rft_id=info:doi/10.1183%2F13993003.00282-2016&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0903-1936&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0903-1936&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0903-1936&client=summon